
2022-05-21 13:38:14
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older Injection is the first indicated treatment for EoE ...
Find out More2022-09-20 14:45:45
2022-05-21 13:38:14
Dupixent® Receives FDA Approval to Treat EoE in People Ages 12 and Older Injection is the first indicated treatment for EoE ...
Find out More2021-12-23 13:41:36
FDA denies approval of TAK-721 (budesonide oral suspension) for EoE Takeda, the pharmaceutical company developing TAK-721 (budesonide oral sus ...
Find out More2020-09-09 11:10:41
For Immediate Release ...
Find out More2020-03-08 21:01:00
The American Partnership for Eosinophilic Disorders (APFED) is closely monitoring developments regarding the novel coronavirus (COVID-19) outbreak and the poten ...
Find out More